Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02301039
Title A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sarcoma Alliance for Research through Collaboration
Indications

malignant peripheral nerve sheath tumor

liposarcoma

medulloblastoma

synovial sarcoma

leiomyosarcoma

fibrous histiocytoma

Therapies

Pembrolizumab

Age Groups: adult | child
Covered Countries USA

Facility Status City State Zip Country Details
University of Southern California Los Angeles California 90033 United States Details
Medstar Health Research Institute Washington District of Columbia 20010 United States Details
Mayo Clinic Florida Jacksonville Florida 32224 United States Details
H. Lee Moffitt Cancer Center Tampa Florida 33612 United States Details
University of Michigan Ann Arbor Michigan 48109 United States Details
Mayo Clinic Cancer Center Rochester Minnesota 55905 United States Details
Washington University in St. Louis Saint Louis Missouri 63110 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Duke University Durham North Carolina 27705 United States Details
Oregon Health and Science University Portland Oregon 97201 United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 United States Details
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field